 Drug Evaluation, Preclinical
"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
| Descriptor ID |
D004353
|
| MeSH Number(s) |
E05.295.750 E05.337.550
|
| Concept/Terms |
Drug Evaluation, Preclinical- Drug Evaluation, Preclinical
- Drug Evaluations, Preclinical
- Drug Screening
- Drug Screenings
- Screening, Drug
- Screenings, Drug
- Evaluation Studies, Drug, Pre-Clinical
- Preclinical Drug Evaluations
- Evaluation, Preclinical Drug
- Evaluations, Preclinical Drug
- Preclinical Drug Evaluation
- Drug Evaluation Studies, Preclinical
- Evaluation Studies, Drug, Preclinical
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".
This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1986 | 0 | 4 | 4 | | 1987 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1989 | 0 | 3 | 3 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 4 | 6 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 4 | 5 | | 2011 | 2 | 7 | 9 | | 2012 | 0 | 5 | 5 | | 2013 | 1 | 4 | 5 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 6 | 6 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 4 | 4 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 3 | 4 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Marinec PS, Landgraf KE, Uppalapati M, Chen G, Xie D, Jiang Q, Zhao Y, Petriello A, Deshayes K, Kent SBH, Ault-Riche D, Sidhu SS. A Non-immunogenic Bivalent d-Protein Potently Inhibits Retinal Vascularization and Tumor Growth. ACS Chem Biol. 2021 03 19; 16(3):548-556.
-
Prescott K, Jacobs M, Stock W, Wynne J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
-
Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, Tang X, Yaron TM, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen DT, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021 01; 589(7841):270-275.
-
Pimentel MB, Borges FTP, Teymour F, Zaborina OY, Alverdy JC, Fang K, Hong SH, Staneviciute A, He YJ, Papavasiliou G. An in vitro tissue model for screening sustained release of phosphate-based therapeutic attenuation of pathogen-induced proteolytic matrix degradation. J Mater Chem B. 2020 03 25; 8(12):2454-2465.
-
Aggarwal M, Leser GP, Lamb RA. Repurposing Papaverine as an Antiviral Agent against Influenza Viruses and Paramyxoviruses. J Virol. 2020 02 28; 94(6).
-
Yu L, Wei F, Liang J, Ren G, Liu X, Wang CZ, Yuan J, Zeng J, Luo Y, Bi Y, Yuan CS. Target Molecular-Based Neuroactivity Screening and Analysis of Panax ginseng by Affinity Ultrafiltration, UPLC-QTOF-MS and Molecular Docking. Am J Chin Med. 2019; 47(6):1345-1363.
-
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38.
-
Leroux F, Bosc D, Beghyn T, Hermant P, Warenghem S, Landry V, Pottiez V, Guillaume V, Charton J, Herledan A, Urata S, Liang W, Sheng L, Tang WJ, Deprez B, Deprez-Poulain R. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur J Med Chem. 2019 Oct 01; 179:557-566.
-
Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.
-
Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Exp Hematol. 2018 11; 67:60-64.e2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|